Federal pre-emption — a widely used and often effective defense by big business against state tort lawsuits — will be a much harder argument to win because of a recent U.S. Supreme Court ruling, and not just in suits against the pharmaceutical industry, but in a broad swath of suits involving regulated industries — from railroad cars to pesticides to consumer products, according to plaintiffs' and defense attorneys.